The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...

Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades. The FDA says the okay ...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

Senior Advocate Diya Kapur, representing the petitioner, informed the court that some gyms were promoting these drugs as a ...

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

The company is seeking regulatory approval of generic Ozempic by September from Canadian authorities, along with other ...

The Delhi High Court on Tuesday disposed of a public interest litigation (PIL) raising alarm over the off-label and ...

Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...